ArticleAmerican journal of translational research2021
Effect of thalidomide combined with TP chemotherapy on serum VEGF and NRP-1 levels advanced esophageal cancer patients.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- SALL4 promotes angiogenesis in gastric cancer by regulating VEGF expression and targeting SALL4/VEGF pathway inhibits cancer progression.Cancer cell international · 2023Article
- Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview.Metabolites · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the effect of thalidomide combined with pacilitaxel plus cisplatin (TP) chemotherapy on serum vascular endothelial growth factor (VEGF) and neuropilin-1 (NRP-1) levels in advanced esophageal cancer patients.
methodA total of 133 patients with advanced esophageal cancer receiving treatment in Danzhou People's Hospital from February 2017 to July 2019 were recruited and divided into a control group (CG, n = 53) and a study group (SG, n = 80) randomly. Patients in the CG (53 cases) were treated with TP chemotherapy, and patients in the SG (80 cases) were treated with thalidomide on the basis above. The general data of the two groups of patients was observed, as well as the therapeutic effect, chemotherapy-related toxicity, and quality of life. Serum vascular endothelial growth factor (VEGF) and neuropilin-1 (NRP-1) levels were tested before and after treatment.
resultsThere was no difference in general data between the two groups (
conclusionThalidomide combined with TP chemotherapy is safe and effective in treating advanced esophageal cancer patients, which reduces patients' serumlevels of VEGF and NRP-1.
Indexed as
Identifiers
34650759PMC8507076W3206505215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.